Chen Haiying, Strappe Padraig, Chen Shuangfeng, Wang Le-Xin
Central Laboratory, and Key Laboratory of Oral Maxillofacial-Head and Neck Medical Biology, Liaocheng People's Hospital, and Affiliated Liaocheng People's Hospital of Shandong University, Liaocheng, Shandong, 252000, China.
School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW 2650, Australia.
Heart Lung Circ. 2014 Jul;23(7):595-601. doi: 10.1016/j.hlc.2014.02.007. Epub 2014 Mar 6.
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by lung endothelial cell dysfunction and vascular remodelling. A number of studies now suggest that endothelial progenitor cells (EPCs) may induce neovascularisation and could be a promising approach for cell based therapy for PAH. On the contrary EPCs may contribute to pulmonary vascular remodelling, particularly in end-stage pulmonary disease. This review article will provide a brief summary of the relationship between PAH and EPCs, the application of the EPCs to PAH and highlight the potential clinical application of the EPCs cell therapy to PAH.
肺动脉高压（PAH）是一种以肺内皮细胞功能障碍和血管重塑为特征的进行性疾病。现在许多研究表明，内皮祖细胞（EPCs）可能诱导新血管形成，并且可能是PAH细胞治疗的一种有前景的方法。相反，EPCs可能促成肺血管重塑，尤其是在终末期肺病中。这篇综述文章将简要总结PAH与EPCs之间的关系、EPCs在PAH中的应用，并强调EPCs细胞治疗在PAH中的潜在临床应用。
